Addendum

Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31

Status
Status: Commission completed
Project no.
G23-20
Last updated

Report documents

  1. Addendum

    Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31

    published on
    Document type
    PDF document, 319 kB, DE, not accessible

Additional information

Federal Joint Committee (G-BA)

05-10-2023 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
G23-20
Commission
Commission awarded on 09.08.2023 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.

Connected Projects

  1. Dossier assessment

    Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-29
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-31
    Last updated

    Status: Commission completed

  3. Addendum

    Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31

    Project no.
    A23-84
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form